Impax Laboratories Inc

Impax Laboratories — Q3 2016 Earnings Presentation

31 slides from Impax Laboratories's earnings presentation, Nov 9, 2016

  1. Slide 1: Third Quarter 2016 Financial Results and Business Update

    1 Third Quarter 2016 Financial Results and Business Update November 9, 2016

  2. Slide 2: Cautionary Statement Regarding Forward Looking Statements

    2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical; these statements are forward-looking in nature and

  3. Slide 3: Agenda

    3 Agenda • 3Q16 Financial Results • Business Update Fred Wilkinson President & CEO • 3Q16 Financial Review • 2016 Financial Guidance Update Bryan Reasons SVP & CFO • Q&A Executive Team

  4. Slide 4: 3Q16 Results and Business Update

    4 3Q16 Results and Business Update Fred Wilkinson President & Chief Executive Officer

  5. Slide 5: 3Q16 and Recent Market Events

    5 • Quarter results essentially in line with our expectations › Marketing and operational strategies drove revenue growth of 112% in Epinephrine Auto-Injector and oxymorphone compared to 3Q15 › Recapturing generic Adderall XR® share but at significantly lower price › Launched 3 generic products • Sh

  6. Slide 6: Year Over Year Change in Generic Volume and Price

    6 Impax Year Over Year Change in Generic Volume and Price Total Generics excluding Teva Transaction 3Q15 4Q15 1Q16 2Q16 3Q16 Volume 27% 106% 53% (11%) 5% Price (3%) (13%) (21%) (19%) (15%) gSolaraze® (Diclofenac sodium gel 3%); gSkelaxin® (Metaxalone) Excluding generic Solaraze® , generic Skelaxin®

  7. Slide 7: Segment Revenue Results

    7 Segment Revenue Results $175 $181 $53 $40 3Q16 3Q15 Third Quarter $ millions Generic • 112% increase in sales of epinephrine auto injector (authorized generic to Adrenaclick®) and oxymorphone • 62% decline in sales of generics Solaraze®, Skelaxin® and Adderall XR® due to significant decline in pri

  8. Slide 8: 2016 Sequential Segment Revenue

    8 2016 Sequential Segment Revenue 1Q16 2Q16 3Q16 Generic $ millions All Other gSolaraze® Teva Transaction $55 $51 $53 1Q16 2Q16 3Q16 Specialty Pharma $ millions $170 $122 $175 Managing Through a Volatile Generic Market

  9. Slide 9: Growing Epinephrine Auto-Injector

    9 Growing Epinephrine Auto-Injector 0% 1% 2% 3% 4% 5% 6% 7% 8% 9% 10% Share Growth in 2016 4% 9% • Continuing to expand production/supply • Strong performance during peak seasonal demand • Exceeding 2016 goal of 1% share growth per quarter • Awareness campaign “The GO-TO-CHOICE” › Media, website, ph

  10. Slide 10: Growing Oxymorphone / Recaptured Generic Adderall XR

    10 Growing Oxymorphone / Recaptured Generic Adderall XR® - Share Growth in 2016 0% 10% 20% 30% 40% 50% 60% 2 0 1 6 /0 1 /0 1 2 0 1 6 /0 1 /1 5 2 0 1 6 /0 1 /2 9 2 0 1 6 /0 2 /1 2 2 0 1 6 /0 2 /2 6 2 0 1 6 /0 3 /1 1 2 0 1 6 /0 3 /2 5 2 0 1 6 /0 4 /0 8 2 0 1 6 /0 4 /2 2 2 0 1 6 /0 5 /0 6 2 0 1 6 /0 5

  11. Slide 11: Status of Generic Product Launches in 2016

    11 Status of Generic Product Launches in 2016 Source of sales data: IMS NPS Sep 2016; Launch/Approval data as of Nov 4, 2016; TA = Tentative Approval U.S. Brand/Generic market sales of $5.3B Progress of Targeted Launches Products Launched through October Products Approved Launched Oxycodone TR ER ta

  12. Slide 12: Investing in Generic R&D – Current Pipeline

    12 Investing in Generic R&D – Current Pipeline Source of sales data: IMS NPA Sept 2016; Pipeline data as of Nov. 4, 2016; FTF=First to file; FTM=First to market Generic Pipeline of 40 Products Current U.S. Brand/Generic Market $20B 20 Pending at FDA -$10B 35% Potential or Confirmed FTF or FTM 20 Und

  13. Slide 13: Focused on Growing CNS Franchise

    13 Focused on Growing CNS Franchise 0.0% 1.0% 2.0% 3.0% 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 CD L D S h a re T R x Monthly TRx and Share of National CD-LD TRx Since Launch Rytary TRx CD-LD Share • Completed sales force expansion and remapped territories in June • Redefined clinical and dos

  14. Slide 14: Rytary Patient Support Program

    14 Rytary® Patient Support Program

  15. Slide 15: Focused on Growing CNS Franchise

    15 Focused on Growing CNS Franchise 0% 25% 50% 2,000 4,000 6,000 8,000 10,000 12,000 14,000 Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nas a l T rip ta n S h a re T R x Monthly TRx and Share of Nasal Triptan TRx TRx Nasal Triptan Share • Consistent performanc

  16. Slide 16: Focused on Growing Emverm

    16 Focused on Growing Emverm® 0% 20% 40% 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 3 /2 5 4 /1 4 /8 4 /1 5 4 /2 2 4 /2 9 5 /6 5 /1 3 5 /2 0 5 /2 7 6 /3 6 /1 0 6 /1 7 6 /2 4 7 /1 7 /8 7 /1 5 7 /2 2 7 /2 9 8 /5 8 /1 2 8 /1 9 8 /2 6 9 /2 9 /9 9 /1 6 9 /2 3 9 /3 0 1 0 /7 1 0 /1 4 1 0 /2 1 1 0 /2 8

  17. Slide 17: IPX203: Product Development Update

    17 IPX203: Product Development Update Investigator Assessment of Motor State Off Time (h) On Time (h) Immediate-release CD-LD 7.3 2.7 Rytary 5.5* 4.4* IPX203 4.6 * + 5.4 * + * p ≤ 0.0002 compared to IR CD-LD + p < 0.05 compared with Rytary Improvement from Baseline in MDS-UPDRS Part III • First pati

  18. Slide 18: Financial Review and 2016 Financial Guidance

    18 Financial Review and 2016 Financial Guidance Bryan Reasons Senior Vice President & Chief Financial Officer

  19. Slide 19: Non-Cash Intangible Impairment Charges

    19 Non-Cash Intangible Impairment Charges 3Q16 Impairment Charges Amount $ millions Teva Transaction • Partial impairment of currently marketed portfolio • Higher value products (for example, budesonide inhalation suspension and propranolol HCl tablets) primarily drove impairment value • In-process

  20. Slide 20: 3Q16 Generic Division Results

    20 3Q16 Generic Division Results $ millions GAAP 3Q16 Adjustments Adjusted 3Q16 GAAP 3Q15 Adjustments Adjusted 3Q15 Adjusted Change Revenues $175.3 --- $175.3 $180.7 --- $180.7 (3.0%) Gross (Loss) Profit ($196.2) $273.1 $76.9 $68.0 $9.3 $77.3 (0.5%) Gross Margin (111.9%) --- 43.8% 37.6% --- 42.8% 1.

  21. Slide 21: 3Q16 Specialty Pharma Division Results

    21 3Q16 Specialty Pharma Division Results $ millions GAAP 3Q16 Adjustments Adjusted 3Q16 GAAP 3Q15 Adjustments Adjusted 3Q15 Adjusted Change Revenues $52.6 --- $52.6 $40.4 --- $40.4 30.1% Gross Profit $30.7 $7.5 $38.2 $25.6 $8.2 $33.8 13.0% Gross Margin 58.4% --- 72.5% 63.3% --- 83.7% (11.2)ppts SG&

  22. Slide 22: 3Q16 Consolidated Results

    22 3Q16 Consolidated Results $ millions GAAP 3Q16 Adjustments Adjusted 3Q16 GAAP 3Q15 Adjustments Adjusted 3Q15 Adjusted Change Revenues $227.9 --- $227.9 $221.1 --- $221.1 3.1% Gross (Loss) Profit ($165.4) $283.4 $115.0 $93.5 $17.6 $111.1 3.5% Gross Margin (72.6%) --- 50.5% 42.3% --- 50.3% 0.2ppts

  23. Slide 23: 2016 Updated Guidance

    23 2016 Updated Guidance Item As of August 9 Updated November 9 Revenue $900M to $940M $840M to $855M Adjusted Gross Margin Low 50% range 48% to 50% Adjusted R&D Expense $100M to $105M $90M to $95M Adjusted SG&A Expense $190M to $200M $185M to $190M Tax Rate 34% to 36% 34% to 35% Adjusted Interest E

  24. Slide 24: Fourth Quarter Priorities

    24 Fourth Quarter Priorities Focus on quality and operations Aggressively pursue share growth within generic portfolio Effectively execute on Rytary® and Emverm® growth initiatives Maximize new generic product launches Continue to pursue organic growth opportunities through R&D Explore additional ex

  25. Slide 25: Q&A

    25 Q&A

  26. Slide 26: Appendix

    26 Appendix

  27. Slide 27: Pending ANDAs at FDA

    27 20 Pending ANDAs at FDA Source of sales data: IMS NPS September 2016; Pipeline data as of November 4, 2016; TA = tentative approval 1 Launched authorized generic in April 2016 2 Assuming final FDA approval, earliest potential launch date/timing based on settlement or patent expiration date First-

  28. Slide 28: GAAP to Adjusted Net Income Reconciliation

    28 GAAP to Adjusted Net Income Reconciliation The following table reconciles reported net loss to adjusted net income. (Unaudited, amounts in thousands, except per share and per share data) Three months ended September 30, 2016 2015 Net (loss) income $ (179,337) $ 35,755 Adjusted to add (deduct): Am

  29. Slide 29: GAAP to Adjusted Results Reconciliation

    29 GAAP to Adjusted Results Reconciliation The following table reconciles total Company reported cost of revenues to adjusted cost of revenues. (Unaudited, amounts in thousands) Refer to the Third Quarter 2016 Earnings Release for an explanation of adjusted items. (a) Adjusted gross profit is calcul

  30. Slide 30: Generic Division GAAP to Adjusted Results Reconciliation

    30 Generic Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Generics Division reported cost of revenues to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted operating income. (Unaudited, amounts in thousands) Refer to the Th

  31. Slide 31: Specialty Pharma Division GAAP to Adjusted Results Reconciliation

    31 Specialty Pharma Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Specialty Pharma Divisions reported cost of revenues to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted operating income. (Unaudited, amounts in thousand

Impax Laboratories — Q3 2016 Earnings Presentation on 6ix